A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery
Enhancement of Tissue Preservation During Cardiopulmonary Bypass With HBOC-201 (Registry Study)
Sponsor: Biopure Corporation
Listed as NCT00301535, this PHASE2 trial focuses on Coronary Artery Disease and remains ongoing. Sponsored by Biopure Corporation, it has been updated 5 times since 2006, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Feb 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biopure Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Headington, United Kingdom
- • Johannesburg, South Africa
- • Thessaloniki, Greece